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Abstract 
Enterococci are a leading cause of healthcare-associated infections world-wide and display 
increasing levels of resistance to many of the commonly used antimicrobials, making treatment 
of their infections challenging. Combinations of antibiotics are occasionally employed to treat 
serious infections allowing for the possibility of synergistic killing.  
The aim of this study was to evaluate the effects of different antibacterial combinations 
against enterococcal isolates using an in vitro approach and in vivo Galleria mellonella infection 
model. 
Five Enterococcus faecalis and three E. faecium strains were screened by paired 
combinations of rifampicin, tigecycline, linezolid, or vancomycin, using a chequerboard dilution 
method. Antibacterial combinations that displayed synergy were selected for in vivo testing 
using a G. mellonella larvae infection model. 
Rifampicin was an effective antibacterial enhancer when used in combination with 
tigecycline or vancomycin, with minimum inhibitory concentrations (MICs) of each individual 
antibiotic being reduced by between 2- and 4-doubling dilutions, generating fractional inhibitory 
concentration index (FICI) values between 0.31 and 0.5. Synergy observed with the 
chequerboard screening assays was subsequently observed in vivo using the G. mellonella 
model, with combination treatment demonstrating superior protection of larvae post-infection in 
comparison to antibiotic monotherapy. In particular, rifampicin in combination with tigecycline 
or vancomycin significantly enhanced larvae survival.  
The addition of rifampicin to anti-enterococcal treatment regimens warrants further 
investigation and may prove useful in the treatment of enterococcal infections, whilst prolonging 
the clinically useful life of currently active antibiotics. 
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1. Introduction 
Enterococci cause a spectrum of infections from uncomplicated urinary tract infection to life-
threatening endocardial and device-related infections. These pathogens are intrinsically resistant 
to a number of commonly used antimicrobials and have a remarkable ability to acquire new 
resistance mechanisms. This situation has fuelled global concern over future treatment options 
for serious enterococcal infections caused by multi-drug resistant strains.  
Antibacterial agents commonly utilised or recently developed for the treatment of 
enterococcal infections include vancomycin, linezolid, daptomycin, telavancin and dalbavancin. 
Tigecycline has been suggested as an alternative therapy, but with the exception of intra-
abdominal infections, a current lack of clinical data has impeded greater use [1]. As resistance to 
many of these antibacterials increases, including tigecycline [2], therapeutic options become 
progressively more limited and the need for strategies to protect against further loss of activity 
becomes paramount. 
Prescribing antibacterial combinations is established clinical practice for treatment of 
serious infections. There are several potential advantages to combined therapy: enhanced killing 
effect and the possibility of synergy, a reduction in the concentration of individual agents 
required (reduced toxicity, selection pressure), and of vital importance, the ability to protect 
against development of resistance. Daptomycin is, for example, recommended as part of a 
combined therapy for serious infections [3, 4]. Rifampicin is rapidly bactericidal against many 
Gram-positive bacteria and displays good tissue penetration, but the rapid development of 
resistance precludes its use as monotherapy [4] leading to this old agent often being considered 
specifically for use in combination therapy [5, 6]. 
The aim of this study was to describe the killing effect of different antibacterial 
combinations against clinical enterococcal isolates using standard methods and the in vivo G. 
mellonella infection model. 
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2. Material and methods 
2.1 Bacterial isolates and growth conditions 
Eight enterococcal isolates were studied: including three vancomycin sensitive strains; E. 
faecalis ATCC 29212, E. faecalis clinical isolates E019 and E045; as well as four vancomycin 
resistant strains; E. faecalis ATCC 51299, E. faecium ATCC 51559, E. faecium clinical isolates 
E022, E039; and one tigecycline resistant E. faecalis UW6940 (supplied by Dr Werner) (Table 
1).   
2.2 Preparation of antibiotics 
Vancomycin and rifampicin were purchased from Sigma-Aldrich (Sigma-Aldrich, Dorset, UK). 
Linezolid and tigecycline were gifted from Pfizer (Pfizer Ltd, Surrey, UK). Antibiotic stocks of 
10,000 mg/L (except linezolid 1,000 mg/L) were freshly prepared using distilled water each day 
(linezolid and tigecycline) or stored at -20°C for a maximum of one week (vancomycin and 
rifampicin). 
2.3Antibiotic susceptibility testing 
The minimum inhibitory concentration (MIC) of antibiotics was determined by the broth 
microdilution method described by the British Society for Antimicrobial Chemotherapy (BSAC) 
for each of the eight isolates [7].  E. faecalis ATCC 29212 was included as a control strain in 
each experiment; all results were within guideline limits.  MICs were performed in duplicate and 
repeated on two further occasions. 
2.4 Antibacterial combination assays 
Standard chequerboard assays were performed in 96-well microtitre plates with doubling 
dilutions of each antibiotic prepared in Muller Hinton broth. The final sub-MIC ranges used for 
vancomycin, rifampicin, tigecycline and linezolid were 0.12-1024 mg/L, 0.12-32 mg/L, 0.007-4 
mg/L and 0.12-8 mg/L, respectively. An equal volume of standardised bacterial suspension 
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5x105 CFU/ml was added before plates were incubated at 37°C in air for 24 h. Fractional 
inhibitory concentrations (FICs) were calculated as the MIC of drug A or B in combination 
divided by the MIC of drug A or B alone, respectively, and the FIC index (FICI) was obtained 
by adding the two FIC values. The drug combination that consistently generated the lowest FICI 
after repeating the experiment in duplicate on two further occasions was used to categorise 
results as follows: FICIs of <0.5 were interpreted as synergistic, those >0.5 but <4 were 
considered as no interaction, and those above >4 were interpreted as antagonistic [8]. 
Combinations demonstrated to be synergistic were assessed using the G. mellonella infection 
model. 
2.5 G. mellonella infection model 
G. mellonella wax moth larvae (Livefood UK Ltd) in their final instar stage of development 
were stored at room temperature in the dark and used within one week of delivery. Healthy 
larvae, without grey markings and of a similar weight (200-300 mg), were selected and split into 
experimental groups of 15 [9].  Bacterial suspensions of each isolate were prepared based on a 
pre-optimised dose (1x106–5x106 CFU/larva) which caused >80% larvae deaths at 72 h post-
infection (Supplemental Data Fig. 1).  
After sterilisation of the inoculation site with 70% (v/v) ethanol, the last right proleg was 
used to deliver 10 µl of bacterial suspension (recorded in Fig. 1) into the hemocoel (primary 
body cavity) using a 1/2 inch, 30 gauge needle (BD precisionglide® syringe needle, Sigma) 
attached to a 50 µl Hamilton syringe (1705 TLL, Jaytee Biosciences, UK). Antimicrobial drugs 
(used at 1xMIC as monotherapy or between 1/4xMIC and 1/16xMIC for antibacterial 
combinations) were delivered into the hemocoel via a 10 µl injection into the last left proleg 
(n=15). The larvae were incubated in vented plastic petri dishes at 37°C in air and deaths were 
scored through observation of melanisation and failure of larvae to move in response to touch at 
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time points 12, 24, 48, 72 and 96 h. Appropriate uninfected and vehicle controls were included 
for each experiment. 
Pooled data from three independent experiments, using G. mellonella larvae obtained 
from different batches, was assessed using the Kaplan-Meier method and treatment groups were 
compared using the logrank (Mantel-Cox) test (GraphPad Prism® 6). P values <0.05 were 
considered statistically significant. 
 
3. Results 
3.1 Assessing the in vitro antimicrobial sensitivities of eight enterococcal isolates using the 
chequerboard dilution method 
Results of susceptibility testing are shown in Table 1. No antimicrobial combination showed an 
antagonistic effect against any of the strains evaluated. Out of the six antimicrobial 
combinations, tested against eight strains, synergy was seen in six cases, but in each case it was a 
rifampicin-containing combination.  Synergy was demonstrated against all vancomycin resistant 
enterococci by at least one rifampicin containing antibacterial combination; all E. faecium 
isolates and one E. faecalis isolate (Tables 1 and 2). 
3.2 Antimicrobial treatment of infected G. mellonella larvae 
Dose-dependent killing of G. mellonella was achieved when larvae were infected with 1x106, 
3x106 or 5x106 CFU/larva of each isolate. E. faecalis ATCC 51299 was highly virulent at all 
three doses tested, whilst E. faecium ATCC 51559, E. faecium E022 and E. faecium E039 were 
less virulent in the G. mellonella model (Supplemental Data Fig. 1). 
Treatment of infected larvae with an antibacterial combination of sub-MIC agents 
consistently led to an increased level of survival (20–73% larvae survival at 96 h with a median 
value of 57%) compared to those treated with a higher concentration of a single agent (7–53% 
survival with a median value of 13%) (Fig. 1). A statistically significant greater level of survival 
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was observed with four of the six combinations tested compared to the untreated control group 
(Fig. 1a, c, e, f), whilst only two vancomycin monotherapies administered at 1xMIC 
significantly improved survival of the G. mellonella compared to the control group (Fig. 1c 
p=0.003, 1e p=0.0159). Furthermore, the combination of rifampicin with tigecycline was 
statistically superior to tigecycline alone (13% larval survival when treated with tigecycline for 
infection with strain E039 versus 60% larval survival when treated with the antimicrobial 
combination; p=0.0237) (Fig. 1f). 
 
 
4. Discussion 
Antibacterial combination are often utilised during treatment of serious infections but the 
superiority of one antibiotic combination over another for the treatment of enterococcal 
infections remains unproven. In this study, it was demonstrated that antimicrobial combinations 
including rifampicin can be synergistic against enterococci but this is not a consistent finding 
among enterococci. 
Though traditionally used in the investigation of antibacterial combinations for 
synergistic activity, chequerboard assays have reproducibility issues and may not adequately 
reflect activity in vivo. The G. mellonella in vivo infection model however, shares some basic 
immunity characteristics with mammals, including the deployment of proteolytic cascades 
(clotting and melanisation) following pathogen recognition [10].  An additional advantage and in 
contrast to mammalian models, G. mellonella can be inexpensively sourced and is not subject to 
animal research legislature [11]. 
In this study the larval model corroborated the in vitro data; treatment with antibacterial 
combinations that were synergistic in vitro improved the survival rate of larvae against those 
treated with a single agent. 
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 All combinations where synergy was detected were performed with concentrations of 
antibacterial below the MIC (1/4-1/16th x MIC) and contained rifampicin; rifampicin with either 
vancomycin or tigecycline being the most effective combinations. Of the five vancomycin or 
tigecycline combinations trialled, a statistically greater proportion of the larvae treated by 
combination therapy survived in four of the assays compared to the wax moths which were 
either untreated or received only one antibiotic.  
Rifampicin is effective against a range of Gram positive pathogens, but the rapid 
development of resistance necessitates that it be used in combination with another agent. Several 
studies have highlighted the synergistic activity of rifampicin with others agents [6, 12], indeed 
rifampicin based combinations, including vancomycin, are recommended for the treatment of 
staphylococcal endocarditis [3]. Combinations incorporating rifampicin are not, however, in 
routine use for treatment of enterococcal infections.  
The classic combination of a cell wall active agent (such as vancomycin or a beta-lactam) 
plus an aminoglycoside results in a synergistic effect against enterococci [13]. High-level 
aminoglycoside resistance has however, led to a reconsideration of this standard treatment 
(gentamicin and ampicillin) resulting, in some instances, to the recommendation of an unusual 
double beta-lactam combination (ampicillin plus ceftriaxone) [14, 15]. In addition, the continual 
rise of vancomycin resistance has limited the value of this agent in the classic treatment and, as a 
consequence, excluded it in many instances from combination therapy studies. Yet a 
vancomycin-based combination has shown efficacy against resistant enterococci [16].  In this 
study, a vancomycin plus rifampicin combination improved the survival rate of G. mellonella 
larvae infected with selected rifampicin and/or vancomycin resistant enterococcal strains.  
Typically, the interaction of tigecycline with other agents results in indifference or 
occasionally antagonism, an exception being with rifampicin [17].  High rates of in vitro 
synergism have been described for tigecycline plus rifampicin against E. faecalis and E. faecium 
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isolates using the chequerboard dilution method [5, 18]. More recently, Silvestri et al. (2012) 
tested tigecycline plus rifampicin combinations in an animal model of surgical wound infections 
and reported good activity against enterococcal isolates [19] supporting the observations 
reported here with the wax moth infection model. 
The failure to assess any reduction in susceptibility to agents during treatment was a 
limitation of the current study since the rapid development of resistance against rifampicin in 
particular will always remain a concern and the observations of Holmberg and Rasmussen 
(2014) indicate that combined therapy might not be sufficient to prevent this from developing 
[20].  
 
In conclusion, the study has revealed the efficacy of rifampicin-based combination therapies 
against some highly-resistant enterococci and further investigation in vivo with additional 
clinically relevant strains is warranted.   
Antibiotic combinations offer the potential to treat problematic antimicrobial resistant 
bacteria with lower concentration of antibiotic without compromising efficacy and with a lower 
risk of adverse side effects. Moreover, combination therapy has the potential to reduce selective 
pressures and help protect the clinical life of agents, particularly newer agents for which little if 
any resistance exists. In addition, the chequerboard assay remains a useful screening tool for 
detection of potentially synergistic antimicrobial combinations, with the wax moth model being 
a practical and superior technique for providing quantitative in vivo data.  
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Table 1. Standard antibiotic susceptibility and antibacterial combination results for eight enterococcal isolates. 
Enterococcal isolate Antibiotic susceptibility MIC 
(mg/L) 
Lowest FICI generated by each drug combinations 
VAN RIF LZD TGC VAN + 
TGC 
VAN + 
RIF 
TGC + 
RIF 
LZD + 
VAN 
LZD + 
TGC 
LZD + 
RIF 
E. faecalis ATCC 29212 2 2 2 0.12 0.62 0.62 0.62 1 1 0.62 
 E019 1 4 2 0.25 1 1 0.75 1 1 0.62 
 E045 2 1 2 0.12 0.75 0.75 0.75 1.5 1 0.75 
 ATCC 51299 64 1 1 0.12 0.62 0.37 0.75 0.75 0.75 0.62 
 UW6940 1 2 1 2 0.75 1 0.75 1 0.75 0.75 
E. faecium ATCC 51559 256 8 2 0.12 1 0.75 0.62 0.56 0.75 0.5 
 E022 512 4 1 0.12 0.62 0.37 0.5 0.56 0.56 0.62 
 E039 512 16 2 0.12 0.75 0.31 0.37 0.62 0.75 0.62 
 
Antibiotics; VAN – vancomycin, RIF – rifampicin, LZD – linezolid, TGC – tigecycline. Antibiotic susceptibilities: VAN, RIF and LZD – sensitive ≤4 mg/L, 
resistant >4 mg/L; TGC – sensitive ≤0.25 mg/L, intermediate 0.5 mg/L, resistant >0.5 mg/L. Impact of antibacterial combinations; synergy = FICI ≤0.5 (shown in 
bold), no interaction = FICI >0.5 - <4, antagonism = >4.  
 
 
 
Table 2. Enterococcal strains which displayed synergy with antibiotic combinations. 
Enterococcal 
isolate 
Antibiotic  
synergistic 
combination 
with RIF 
- Drug A 
MIC of Drug A and RIF alone 
(mg/l) 
Concentration of the drug in 
combination (mg/l) 
Fractional inhibitory 
concentration (FIC) 
Fractional 
inhibitory 
concentration 
index (FICI) 
Drug A RIF Drug A RIF Drug A RIF 
E. faecalis 
ATCC 51299 
VAN 64 1 16 0.12 0.25 0.12 0.37 
E. faecium 
ATCC 51559 
LZD 2 8 0.5 2 0.25 0.25 0.5 
E. faecium 
E022 
VAN 512 4 64 1 0.125 0.25 0.37 
TGC 0.12 4 0.03 1 0.25 0.25 0.5 
E. faecium 
E039 
VAN 512 16 128 1 0.25 0.06 0.31 
TGC 0.12 16 0.03 2 0.25 0.12 0.37 
 
Antibiotics; VAN – vancomycin, RIF – rifampicin,  LZD – linezolid, TGC – tigecycline. 

 
 
Fig. 1. Effect of antibiotic treatment on survival of G. mellonella larvae infected with E. 
faecalis ATCC 51299 (a), E. faecium ATCC 51559 (b), E. faecium E022 (c and d), and E. 
faecium E039 (e and f) (n = 45). VAN, vancomycin; RIF, rifampicin; LZD, linezolid; 
TGC, tigecycline. *** p<0.001, ** p<0.01, *p<0.05 for antibiotic combinations tested 
compared to the untreated control; ^p<0.05 for antibiotic combinations tested compared to 
tigecycline alone. 
 
 
 
 
 
Supplemental Data Fig. 1. Effect of inoculum dose on G. mellonella larva survival. Larvae were inoculated with three bacterial 
concentrations (1x106 CFU/larva, 3x106 CFU/larva and 5x106 CFU/larva in MH broth) of (a) E. faecalis ATCC 51299, (b) E. faecium 
ATCC 51559, (c) E. faecium E022 and (d) E. faecium E039 and deaths recorded at 12, 24, 48 and 72 h to assess lethal doses. 
Experiments were performed three times using different batches of fifteen G. mellonella and the average larvae death at each 
time point were determined (n=45). 
